Loading…

Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease

Mononuclear phagocytes are important modulators of Alzheimer's disease (AD), but the specific functions of resident microglia, bone marrow-derived mononuclear cells, and perivascular macrophages have not been resolved. To elucidate the spatiotemporal roles of mononuclear phagocytes during disea...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of neuroscience 2011-08, Vol.31 (31), p.11159-11171
Main Authors: Mildner, Alexander, Schlevogt, Bernhard, Kierdorf, Katrin, Böttcher, Chotima, Erny, Daniel, Kummer, Markus P, Quinn, Michael, Brück, Wolfgang, Bechmann, Ingo, Heneka, Michael T, Priller, Josef, Prinz, Marco
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mononuclear phagocytes are important modulators of Alzheimer's disease (AD), but the specific functions of resident microglia, bone marrow-derived mononuclear cells, and perivascular macrophages have not been resolved. To elucidate the spatiotemporal roles of mononuclear phagocytes during disease, we targeted myeloid cell subsets from different compartments and examined disease pathogenesis in three different mouse models of AD (APP(swe/PS1), APP(swe), and APP23 mice). We identified chemokine receptor 2 (CCR2)-expressing myeloid cells as the population that was preferentially recruited to β-amyloid (Aβ) deposits. Unexpectedly, AD brains with dysfunctional microglia and devoid of parenchymal bone marrow-derived phagocytes did not show overt changes in plaque pathology and Aβ load. In contrast, restriction of CCR2 deficiency to perivascular myeloid cells drastically impaired β-amyloid clearance and amplified vascular Aβ deposition, while parenchymal plaque deposition remained unaffected. Together, our data advocate selective functions of CCR2-expressing myeloid subsets, which could be targeted specifically to modify disease burden in AD.
ISSN:0270-6474
1529-2401
DOI:10.1523/JNEUROSCI.6209-10.2011